Gilead Sciences Inc (GILD)

[Birdstone]

Data looks fine to me. Sample size is small though and no placebo, so can't draw definite conclusions. However, the results (if confirmed in phase 3) are strong, considering it's only over 24 weeks. My understanding though and looking at the data is that simtuzumab is basically the placebo because it doesn't work. We'll see how the phase 3 data turns out.